Av. Francisco Trein, 596 – 2º andar - Bairro: Cristo Redentor - CEP 91350-200 - Porto Alegre
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Waldo Mattos
Carolina Heidtmann
Aline Santos
Andréa Kremer
Juliana de Menezes
Paula Paz
Leonardo Almeida
Gustavo Alves
Daltro Gilberto Boranga Junior
Franciele de Almeida Menegat
Mirela Gil
Liliana Rockenbach
Laisa Silveira
Mônica Terra Lima
Juliana Yamaguchi
Open studies
Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy - Astefania - Hoffmann-La RocheSee more
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) - heredERA - Hoffmann-La RocheSee more
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer - Hoffmann-La RocheSee more
Advanced tumors
Screening Study for Participants With Malignant Tumors - Hoffmann-La RocheSee more
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors - Immunocore LtdSee more
Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy - IMvigor011 - Hoffmann-La RocheSee more
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Esophageal cancer
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) - Merck Sharp & Dohme LLCSee more
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer - Krascendo 1 - Hoffmann-La RocheSee more
Solid tumors
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors - Immunocore LtdSee more